作者
Wenjun Tang,Jingru Luo,Shu Lin,Qixing Yan
摘要
Background Cisplatin (DDP) is a commonly used first-line chemotherapy drug for non-small cell lung cancer (NSCLC), but the emergence of DDP resistance greatly reduces its therapeutic effect. Arrestin domain-containing 3 (ARRDC3) has been found to play an anti-cancer role in NSCLC, but whether ARRDC3 regulates DDP resistance in NSCLC is still unclear. Methods The levels of ARRDC3, myeloid ecotropic insertion site 1 (MEIS1), protein kinase AMP-activated catalytic subunit alpha 2 (PRKAA2), and autophagy-related proteins were detected by quantitative real-time PCR (qRT-PCR) or western blot. Cell counting kit 8 (CCK8) assay, 3-(4, 5-dimethyl-2-thiazolyl)−2, 5-diphenyl-2H-tetrazolium bromide (MTT) assay, 5-ethynyl-2′-deoxyuridine (EdU) assay, flow cytometry, and transwell assay were used to measure cell DDP resistance, proliferation, apoptosis and invasion. The interaction between ARRDC3 and MEIS1 or PRKAA2 was confirmed by dual-luciferase reporter assay, chromatin immunoprecipitation (ChIP) assay and Co-immunoprecipitation (Co-IP) assay. Xenograft tumor models were constructed to test the effect of ARRDC3 on NSCLC tumorigenesis and DDP resistance in vivo. Results ARRDC3 expression was downregulated in DDP-resistant NSCLC tissues and cells. Functional experiments showed that ARRDC3 overexpression restrained DDP resistance, growth, invasion and autophagy in NSCLC cells. Moreover, MEIS1 promoted ARRDC3 transcription by binding to its promoter region, and the inhibitory effects of MEIS1 overexpression on cell DDP resistance, growth, invasion and autophagy were reversed by ARRDC3 knockdown. Besides, ARRDC3 could interact with PRKAA2, and PRKAA2 overexpression also eliminated the regulation of ARRDC3 on cell DDP resistance, growth, invasion and autophagy. Furthermore, MEIS1 decreased PRKAA2 expression by activating ARRDC3 transcription. Additionally, upregulation of ARRDC3 reduced NSCLC tumorigenesis and DDP resistance in vivo. Conclusion MEIS1-activated ARRDC3 represses NSCLC cell DDP resistance, growth, invasion and autophagy by reducing PRKAA2 expression, confirming the crucial role of MEIS1/ARRDC3/PRKAA2 axis in the chemotherapy resistance of NSCLC.